▁British 8.5703125
▁Bi 8.046875
ote 1.810546875
ch 0.12213134765625
' 5.16796875
s 0.0084686279296875
▁Mar 8.125
im 7.59375
ast 0.63916015625
at 0.0004012584686279297
▁anti 8.7421875
- 0.08404541015625
can 1.4482421875
cer 0.0010814666748046875
▁treatment 3.126953125
▁to 3.53125
▁be 0.9091796875
▁review 4.40625
ed 0.00251007080078125
▁at 3.93359375
▁ES 5.8515625
MO 0.002796173095703125
▁conference 3.60546875
▁in 2.298828125
▁Vienna 2.94921875
▁ 4.83984375
<0x0A> 10.0078125
<0x0A> 8.0703125
B 1.6865234375
rit 0.050323486328125
ish 0.006103515625
▁Bi 0.10662841796875
ote 0.0005769729614257812
ch 0.0117034912109375
, 2.93359375
▁a 0.92431640625
▁leading 2.765625
▁UK 1.6376953125
▁bi 1.0107421875
ote 0.26171875
chn 0.2454833984375
ology 0.0009765625
▁company 0.0782470703125
, 0.6416015625
▁announced 1.525390625
▁today 0.39892578125
▁that 0.07110595703125
▁updated 7.24609375
▁results 1.0908203125
▁from 0.3515625
▁its 1.251953125
▁Ph 0.81201171875
ase 0.00218963623046875
▁III 1.25
▁clin 1.2861328125
ical 0.0006833076477050781
▁trial 0.373291015625
▁of 0.443115234375
▁Mar 1.337890625
im 0.0019283294677734375
ast 4.3392181396484375e-05
at 8.225440979003906e-06
, 1.15625
▁an 1.5419921875
▁investig 2.17578125
ational 0.033843994140625
▁anti 1.7568359375
- 0.01270294189453125
can 0.09967041015625
cer 0.00013375282287597656
▁drug 1.525390625
, 0.43359375
▁will 0.23388671875
▁be 0.005359649658203125
▁presented 0.1556396484375
▁at 0.207763671875
▁the 0.1314697265625
▁European 1.00390625
▁Society 0.0828857421875
▁for 0.12103271484375
▁Medical 0.002227783203125
▁On 0.00225830078125
col 0.003658294677734375
ogy 3.063678741455078e-05
▁( 0.248291015625
ES 0.004093170166015625
MO 0.0001373291015625
) 0.0278778076171875
▁annual 2.921875
▁conference 1.052734375
▁in 0.388916015625
▁Vienna 0.01206207275390625
▁next 3.669921875
▁month 0.7685546875
. 0.12408447265625
▁Mar 3.203125
im 0.0006418228149414062
ast 0.00025725364685058594
at 3.230571746826172e-05
▁is 0.5283203125
▁an 2.541015625
▁or 0.499755859375
ally 0.89794921875
- 1.7109375
active 1.857421875
▁matrix 4.75390625
▁metal 0.024871826171875
lo 0.00040435791015625
prote 0.02569580078125
in 0.06243896484375
ase 0.006168365478515625
▁( 0.54345703125
M 0.01052093505859375
MP 0.00016295909881591797
) 0.09814453125
▁in 0.052642822265625
hib 0.000621795654296875
itor 0.0011339187622070312
▁that 1.6875
▁British 5.765625
▁Bi 0.005847930908203125
ote 0.0010557174682617188
ch 0.0013189315795898438
▁is 0.48193359375
▁developing 0.1829833984375
▁for 0.483154296875
▁the 0.2373046875
▁treatment 0.1279296875
▁of 0.008270263671875
▁g 5.1015625
astro 0.4326171875
int 0.1214599609375
est 1.049041748046875e-05
inal 0.0001709461212158203
▁can 1.751953125
cers 2.1457672119140625e-05
, 1.8076171875
▁including 0.8681640625
▁pan 3.083984375
cre 0.0004107952117919922
atic 0.038848876953125
, 1.3408203125
▁g 1.8759765625
astr 0.042327880859375
ic 9.703636169433594e-05
, 0.61181640625
▁and 2.134765625
▁col 0.2978515625
ore 0.00384521484375
ct 0.0003376007080078125
al 9.107589721679688e-05
▁can 0.65966796875
cers 2.5987625122070312e-05
. 0.213134765625
<0x0A> 0.68994140625
<0x0A> 0.07403564453125
The 1.833984375
▁new 3.625
▁data 0.71533203125
▁will 1.1923828125
▁provide 5.1953125
▁an 1.5986328125
▁analysis 5.2265625
▁of 0.044708251953125
▁overall 2.619140625
▁surv 0.1473388671875
ival 0.000507354736328125
▁from 2.775390625
▁the 0.429443359375
▁double 6.08984375
- 0.13525390625
bl 0.0038909912109375
ind 3.600120544433594e-05
, 0.53271484375
▁place 0.492919921875
bo 0.0001901388168334961
- 0.047821044921875
control 0.005336761474609375
led 0.0004260540008544922
▁trial 1.892578125
▁evalu 5.28515625
ating 7.271766662597656e-05
▁Mar 0.37158203125
im 0.0005125999450683594
ast 0.00017964839935302734
at 0.00015056133270263672
▁in 0.54931640625
▁combination 1.93359375
▁with 0.00518035888671875
▁gem 1.5625
cit 0.004657745361328125
ab 0.00051116943359375
ine 0.0011615753173828125
, 2.13671875
▁a 1.0927734375
▁standard 0.953125
▁chem 0.7822265625
other 0.0014019012451171875
apy 0.177734375
, 2.62109375
▁in 0.437255859375
▁patients 0.431640625
▁with 0.034271240234375
▁advanced 0.984375
▁pan 0.0849609375
cre 0.00010645389556884766
atic 0.00640869140625
▁cancer 0.07781982421875
. 0.1875
▁Pre 3.724609375
vious 1.8408203125
▁results 1.08203125
▁from 0.525390625
▁the 0.435791015625
▁trial 0.57177734375
▁showed 1.228515625
▁the 3.90234375
▁combination 0.755859375
▁significantly 2.64453125
▁improved 0.70458984375
▁pro 2.498046875
gression 0.0004010200500488281
- 0.0682373046875
free 0.0010786056518554688
▁surv 0.011138916015625
ival 0.0002167224884033203
▁compared 1.9765625
▁to 0.413330078125
▁gem 0.50537109375
cit 0.0004703998565673828
ab 0.0001207590103149414
ine 4.982948303222656e-05
▁alone 0.1116943359375
. 0.416259765625
▁The 1.552734375
▁trial 2.259765625
▁en 2.2265625
rolled 0.00437164306640625
▁over 3.669921875
▁ 0.0046234130859375
9 3.572265625
0 0.0992431640625
0 0.00885772705078125
▁patients 0.056365966796875
▁across 2.794921875
▁ 0.3173828125
1 0.88427734375
5 2.03125
0 1.583984375
▁cent 0.99462890625
ers 0.93603515625
▁in 0.1610107421875
▁Europe 2.091796875
, 0.59033203125
▁Australia 2.62890625
, 0.289794921875
▁Canada 2.45703125
▁and 1.10546875
▁the 0.681640625
▁United 0.82275390625
▁States 0.005382537841796875
. 0.1842041015625
<0x0A> 0.473388671875
<0x0A> 0.0172576904296875
“ 3.44140625
We 1.6943359375
▁are 0.3388671875
▁very 1.3984375
▁pleased 0.53515625
▁to 0.51611328125
▁have 1.6142578125
▁the 1.0927734375
▁opportunity 0.61328125
▁to 0.0269317626953125
▁present 0.317138671875
▁these 1.07421875
▁important 1.771484375
▁new 2.20703125
▁data 0.81591796875
▁on 2.28125
▁overall 4.44921875
▁surv 0.003604888916015625
ival 2.968311309814453e-05
▁with 4.76953125
▁Mar 0.1656494140625
im 0.00021064281463623047
ast 0.00012063980102539062
at 0.0001291036605834961
▁at 0.95556640625
▁the 1.1103515625
▁ES 0.36865234375
MO 3.9577484130859375e-05
▁conference 0.425048828125
,” 0.58251953125
▁said 0.2181396484375
▁Dr 1.6923828125
. 0.1741943359375
▁Peter 3.37890625
▁Parker 7.48828125
, 0.01544952392578125
▁Chief 1.38671875
▁Medical 1.46484375
▁Officer 0.01195526123046875
▁at 1.9150390625
▁British 0.006549835205078125
▁Bi 0.0029430389404296875
ote 0.0014600753784179688
ch 0.0016851425170898438
. 0.04656982421875
▁“ 0.04254150390625
Pan 3.6953125
cre 0.00011527538299560547
atic 0.004119873046875
▁cancer 0.00948333740234375
▁remains 1.962890625
▁an 2.181640625
▁area 0.501953125
▁of 0.06439208984375
▁high 1.2607421875
▁un 0.07208251953125
met 7.164478302001953e-05
▁medical 0.462158203125
▁need 0.0028362274169921875
, 0.90576171875
▁and 0.49267578125
▁we 1.111328125
▁believe 1.001953125
▁Mar 1.818359375
im 0.0002295970916748047
ast 0.00011241436004638672
at 0.0001188516616821289
▁has 1.08984375
▁the 0.162109375
▁potential 0.00830078125
▁to 0.009307861328125
▁become 2.22265625
▁an 0.72216796875
▁important 0.062042236328125
▁new 0.4677734375
▁treatment 0.39794921875
▁option 0.446044921875
▁for 0.1749267578125
▁patients 0.64501953125
▁with 0.9814453125
▁this 0.3759765625
▁dev 1.2919921875
ast 6.401538848876953e-05
ating 0.0005335807800292969
▁disease 0.07684326171875
.” 0.18310546875
<0x0A> 0.0625
<0x0A> 0.0169219970703125
B 2.9140625
rit 0.0181732177734375
ish 0.00011026859283447266
▁Bi 0.0022430419921875
ote 0.0009102821350097656
ch 0.0013227462768554688
▁also 3.4453125
▁plans 1.3359375
▁to 0.0019683837890625
▁meet 4.4140625
▁with 0.021148681640625
▁the 1.03125
▁European 1.0849609375
▁Medic 0.23828125
ines 8.285045623779297e-05
▁Agency 0.0250396728515625
▁( 0.2822265625
EMA 0.00878143310546875
) 0.04486083984375
▁and 2.634765625
▁U 2.583984375
. 0.00021505355834960938
S 0.0030193328857421875
. 0.004367828369140625
▁Food 0.0304718017578125
▁and 0.04473876953125
▁D 0.0002675056457519531
rug -0.0
▁Administration 0.0010499954223632812
▁( 0.01148223876953125
F 0.0022678375244140625
DA 1.7762184143066406e-05
) 0.01189422607421875
▁in 1.3310546875
▁the 0.50146484375
▁coming 0.634765625
▁months 0.267822265625
▁to 0.119140625
▁discuss 0.139892578125
▁fil 5.5859375
ing 0.01314544677734375
▁for 2.3203125
▁market 0.73291015625
ing 0.0889892578125
▁appro 0.375732421875
val 1.4066696166992188e-05
▁of 0.5546875
▁Mar 0.0290985107421875
im 0.00029921531677246094
ast 6.031990051269531e-05
at 2.7418136596679688e-05
▁based 3.955078125
▁on 0.00806427001953125
▁the 0.44384765625
▁final 4.9296875
▁data 2.31640625
▁from 0.061248779296875
▁this 1.7451171875
▁trial 0.55859375
. 0.134765625
▁Mar 3.794921875
im 0.00017905235290527344
ast 3.254413604736328e-05
at 9.202957153320312e-05
▁has 1.34765625
▁been 0.9462890625
▁granted 0.50634765625
▁Or 1.1298828125
phan 2.384185791015625e-05
▁D 0.04339599609375
rug 0.00045943260192871094
▁status 1.22265625
▁for 1.646484375
▁pan 1.63671875
cre 4.4465065002441406e-05
atic 0.0034122467041015625
▁cancer 0.10882568359375
▁in 0.619140625
▁both 0.50146484375
▁the 0.389892578125
▁EU 2.501953125
▁and 0.0019216537475585938
▁U 1.8466796875
. 6.377696990966797e-05
S 0.00034546852111816406
. 0.2449951171875
▁British 5.70703125
▁Bi 0.0015087127685546875
ote 1.9431114196777344e-05
ch 0.0003657341003417969
▁previously 4.6015625
▁reported 2.509765625
▁the 3.55078125
▁trial 4.078125
▁met 0.7939453125
▁its 0.1551513671875
▁primary 0.173828125
▁endpoint 0.157958984375
▁of 0.24462890625
▁pro 0.478271484375
gression 4.7206878662109375e-05
- 0.06475830078125
free 0.0013570785522460938
▁surv 0.001544952392578125
ival 2.3365020751953125e-05
, 1.76953125
▁but 3.546875
▁the 1.7548828125
▁data 2.45703125
▁on 3.380859375
▁overall 0.0538330078125
▁surv 0.0035037994384765625
ival 1.2159347534179688e-05
▁was 1.3056640625
▁not 0.5498046875
▁yet 1.6279296875
▁m 0.5009765625
ature 3.647804260253906e-05
▁at 1.3916015625
▁the 0.79248046875
▁time 0.016143798828125
▁of 0.59814453125
▁that 1.7470703125
▁analysis 3.154296875
. 0.039031982421875
<0x0A> 0.3046875
<0x0A> 0.0078582763671875
The 1.974609375
▁ES 0.98974609375
MO 4.0411949157714844e-05
▁annual 2.205078125
▁conference 0.4501953125
▁is 1.041015625
▁the 1.1787109375
▁pre 4.4296875
em 0.376708984375
inent 4.0531158447265625e-05
▁European 2.1796875
▁event 2.1171875
▁in 2.1796875
▁on 1.2958984375
col 0.0034027099609375
ogy 2.384185791015625e-06
, 0.87646484375
▁bringing 2.185546875
▁together 0.024688720703125
▁leading 2.251953125
▁on 2.62890625
col 0.708984375
ogy 3.7789344787597656e-05
▁profession 1.7333984375
als 9.369850158691406e-05
▁and 2.53125
▁research 1.24609375
ers 0.0152435302734375
▁from 0.31787109375
▁around 0.151123046875
▁the 0.0006165504455566406
▁world 0.062164306640625
▁to 0.70263671875
▁present 1.0361328125
▁and 0.446533203125
▁discuss 0.039215087890625
▁the 0.40234375
▁latest 0.0445556640625
▁research 1.92578125
▁find 2.30859375
ings 5.245208740234375e-06
▁in 1.3828125
▁clin 2.904296875
ical 0.0004177093505859375
▁on 0.2958984375
col 0.0002586841583251953
ogy 2.5033950805664062e-06
. 0.09539794921875
▁The 0.74365234375
▁conference 0.740234375
▁will 0.470458984375
▁be 0.58056640625
▁held 0.017364501953125
▁from 1.6240234375
▁September 0.358642578125
▁ 0.0005064010620117188
2 0.9189453125
7 2.609375
▁to 1.037109375
▁October 0.434814453125
▁ 0.0007433891296386719
1 0.0261383056640625
▁in 1.048828125
▁Vienna 0.00807952880859375
, 0.26416015625
▁Austria 0.0196075439453125
. 0.05267333984375
